Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Danish pharma major Novo Nordisk (NOV: N) has announced an investment of $1.1 billion to expand its production facility in Brazil’s Montes Claros, northern Minas Gerais, with the aim of increasing ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

It has been a tough period for Novo Nordisk shareholders. In the summer of 2024, the share price was over DKK 1,000 per share. Now it is approaching DKK 400.The latest dip comes on Wednesday morning ...

Brazil represents one of Novo Nordisk’s top five markets. Image credit: Shutterstock/ hyotographics. Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its facility in Minas Gerais, southeast Brazil. The 74,000-sq-m project will be used ...

Novo Nordisk A/S Stock Performance Shares of NYSE NVO opened at $63.52 on Tuesday. The stock’s 50-day moving average is $80.37 and its 200 day moving average is $95.75. The stock has a market ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.